Full Breakdown
Blackstone and TPG Acquire Hologic for $18.3 Billion
10/25/2025, 1:01:17 PM
Overview of the Acquisition
Medical diagnostics company Hologic has entered into a definitive agreement to be acquired by private equity firms Blackstone and TPG in a transaction valued at up to $18.3 billion. Under the terms of the agreement, Blackstone and TPG will purchase all outstanding shares of Hologic at $76 per share in cash, with an additional contingent value right worth up to $3 per share based on revenue performance targets for Hologic’s breast health division in fiscal years 2026 and 2027. This acquisition represents one of the largest healthcare take-private transactions announced in 2025 and is expected to close in the first half of 2026, pending regulatory approvals and shareholder consent.
Background and Context
Hologic, based in Massachusetts, specializes in women’s health diagnostics, including technologies for breast and cervical cancer screening. The company has faced challenges such as declining demand following the COVID-19 pandemic and increased competition in its core segments. This acquisition follows a series of discussions between Hologic and the private equity firms, with an earlier offer reportedly rejected in May 2025.
Implications for the Diagnostics Sector
The acquisition of Hologic is part of a broader trend of consolidation in the in vitro diagnostics (IVD) industry, which has seen significant transactions recently, including the merger between BD and Waters Corporation. Analysts note that Hologic’s sale, which comes at a 4.5x multiple, reflects ongoing investor confidence in the IVD sector despite market volatility. Bruce Carlson, an IVD market specialist, remarked that the multiple suggests investors are looking to capitalize on high valuations rather than exiting the business.
Official Statements & Responses
Stephen P. MacMillan, Hologic's Chairman, President, and CEO, stated, “With their resources, expertise and commitment to women’s health, Blackstone and TPG will help accelerate our growth and enhance our ability to deliver critical medical technologies to customers and their patients around the world.” He also emphasized that the transaction provides immediate and compelling value to Hologic stockholders.
Criticism & Opposition
While the acquisition has been generally viewed positively, some analysts express caution regarding the overall market conditions and potential impacts on profitability. Concerns have been raised about the sustainability of high valuations in the diagnostics sector, particularly in light of recent economic uncertainties.
Conflicting Reports & Gaps
There is a notable discrepancy regarding the valuation of Hologic. The deal represents a 46% premium over Hologic’s share price prior to the acquisition discussions, but some analysts question whether this premium accurately reflects the company's long-term growth potential amidst ongoing market challenges.
What's Next
The acquisition is expected to close in the first half of 2026, contingent on shareholder and regulatory approvals. Investors will be closely monitoring the Federal Reserve's upcoming meeting and economic indicators that could influence market sentiment and borrowing costs, which are critical for Blackstone's business model. Additionally, the performance of Hologic post-acquisition will be a focal point for stakeholders in the diagnostics sector.
Verbatim Quotes
- “This transaction delivers immediate and compelling value to Hologic stockholders, reflecting the dedication of our employees whose hard work has made this milestone possible.” — Stephen P. MacMillan, Chairman, President, and CEO of Hologic
- “BTIG analyst Ryan Zimmerman called the price “fair for all parties” and said the deal is positive for the broader healthcare sector .” — Ryan Zimmerman, Analyst at BTIG
